Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen M Westerhout

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 16, 2009
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cellsJan J Molenaar, Marli E Ebus, Dirk Geerts, et al.
BMC Cancer|July 14, 2012
Identification of BIRC6 as a novel intervention target for neuroblastoma therapyFieke Lamers, Linda Schild, Jan Koster, et al.
European Journal of Cancer (Oxford, England : 1990)|February 28, 2012
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growthFieke Lamers, Linda Schild, Ilona J M den Hartog, et al.
Genes, Chromosomes & Cancer|October 29, 2011
Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosisJan J Molenaar, Jan Koster, Marli E Ebus, et al.
Aging Cell|January 8, 2023
FOXO3A-short is a novel regulator of non-oxidative glucose metabolism associated with human longevityEvan E Santo, Rasmus Ribel-Madsen, Peter J Stroeken, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
JCI Insight|August 9, 2022
DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaThale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, et al.
Scientific Reports|November 27, 2025
Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastomaElien Hilgert, Christophe Van Neste, Sarah-Lee Bekaert, et al.
Ebiomedicine|March 3, 2019
Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathwayThijs van Montfort, Renée van der Sluis, Gilles Darcis, et al.
Nature Communications|April 6, 2019
A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastomaTim van Groningen, Nurdan Akogul, Ellen M Westerhout, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|June 16, 2009
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cellsJan J Molenaar, Marli E Ebus, Dirk Geerts, et al.
BMC Cancer|July 14, 2012
Identification of BIRC6 as a novel intervention target for neuroblastoma therapyFieke Lamers, Linda Schild, Jan Koster, et al.
European Journal of Cancer (Oxford, England : 1990)|February 28, 2012
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growthFieke Lamers, Linda Schild, Ilona J M den Hartog, et al.
Genes, Chromosomes & Cancer|October 29, 2011
Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosisJan J Molenaar, Jan Koster, Marli E Ebus, et al.
Aging Cell|January 8, 2023
FOXO3A-short is a novel regulator of non-oxidative glucose metabolism associated with human longevityEvan E Santo, Rasmus Ribel-Madsen, Peter J Stroeken, et al.
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
JCI Insight|August 9, 2022
DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaThale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, et al.
Scientific Reports|November 27, 2025
Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastomaElien Hilgert, Christophe Van Neste, Sarah-Lee Bekaert, et al.
Ebiomedicine|March 3, 2019
Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathwayThijs van Montfort, Renée van der Sluis, Gilles Darcis, et al.
Nature Communications|April 6, 2019
A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastomaTim van Groningen, Nurdan Akogul, Ellen M Westerhout, et al.
Pageof 3